APTX - Why Aptinyx Stock Is Soaring Today
Shares of the clinical-stage biotech Aptinyx (NASDAQ: APTX) are up by an eye-catching 55% as of 9:55 a.m. Tuesday morning. The drugmaker's stock is ripping higher in response to a positive midstage trial for its post-traumatic stress disorder (PTSD) candidate known as NYX-783.
Before the opening bell, Aptinyx announced that NYX-783 exhibited statistically significant and clinically meaningful efficacy results in a midstage trial consisting of 153 patients with PTSD. Equally as important, the company also reported that the drug showed a favorable adverse event and tolerability profile in the study.
Image source: Getty Images.
For further details see:
Why Aptinyx Stock Is Soaring Today